FDA Calls Out Amgen Over Misleading Anemia Drug Claims

By Jeff Overley (November 22, 2013, 5:05 PM EST) -- Direct mailers from Amgen Inc. oversold the benefits of anemia drug Aranesp and omitted important information about its potential to cause heart attacks and strokes, according to a U.S. Food and Drug Administration letter released Friday....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Related Sections


Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!